BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Murphy CK, O’Donnell MM, Hegarty JW, Schulz S, Hill C, Ross RP, Rea MC, Farquhar R, Chesnel L. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivoWorld J Gastrointest Pathophysiol 2023; 14(4): 71-85 [PMID: 37727283 DOI: 10.4291/wjgp.v14.i4.71]
URL: https://www.wjgnet.com/2150-5330/full/v14/i4/71.htm
Number Citing Articles
1
Mithu Howlader, Shuvo Chandra Das, Shipan Das Gupta, Dhirendra Nath Barman, Mohammed Mafizul Islam, Md. Easin Mia, Md. Salahuddin, Md. Murad Hossain. An Insight into Bacteriocins for Combating Microbial Infections and Ensuring Food SafetyInternational Journal of Peptide Research and Therapeutics 2025; 31(2) doi: 10.1007/s10989-025-10691-5
2
Sophie Irwin, Andrea Chupina Estrada, Becca Nelson, Ashlen Bullock, Berkeley Limketkai, Wendy Ho, Susan Acton, Laurent Chesnel, Hon Wai Koon. ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier functionFrontiers in Microbiology 2024; 14 doi: 10.3389/fmicb.2023.1284083
3
Ivan Sugrue, R. Paul Ross, Colin Hill. Bacteriocin diversity, function, discovery and application as antimicrobialsNature Reviews Microbiology 2024; 22(9): 556 doi: 10.1038/s41579-024-01045-x
4
Susan Acton, Michelle M. O’Donnell, Kalaichitra Periyasamy, Bharat Dixit, Haifeng Eishingdrelo, Colin Hill, R. Paul Ross, Laurent Chesnel. LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease modelsBrain, Behavior, and Immunity 2024; 121: 384 doi: 10.1016/j.bbi.2024.08.024